Personalized guidance for menopausal hormone therapy
Funded at Fred Hutchinson Cancer Center · NIH-11425194 · Data updated 2026-11-12
A new program aims to give individualized risk guidance for menopausal hormone therapy to help women make safer, informed decisions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 15, 2026 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $3,350,648 |
| NIH project number | 1RF1AG102732-01 |
| Project ID | NIH-11425194 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adult women considering or using menopausal hormone therapy who are seeking personalized risk information.
✕Less likely to help
Patients not considering MHT or those for whom no risk estimates can be generated with the developed scores.
What this research studies
This project will create scores that combine medical, demographic, and genetic factors to estimate how MHT could affect risks like breast cancer, stroke, and diabetes. It will also define what an MHT risk communication and decision-support tool should look like and will involve women and healthcare providers in designing a prototype. The work will test generalizability of existing risk scores and adapt them for broader clinical use, with the goal of translating results into patient-friendly guidance.
Why it matters
Potential benefit: If successful, patients could receive personalized risk information that supports safer MHT choices.
How similar studies have gone: Prior risk scores exist but this project plans to adapt and co-design a patient-centered tool, representing a meaningful advancement.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Meisner, Allison — Fred Hutchinson Cancer Center
- Study coordinator: Meisner, Allison
Related research
Other NIH-funded projects on the same topics.
-
How brain glia prune neuron fragments in a worm model
Researchers study how brain support cells called glia remove pieces of living neurons in a tiny worm to learn about brain aging and diseases like Alzheimer's.
-
Understanding and Targeting Lineage Plasticity in Prostate Cancer with Genomic-Based Neoadjuvant Therapy
A broad research program at Fred Hutchinson Cancer Center is exploring how aggressive prostate cancers change their cell states in response to therapy and how to block these changes.
-
Personalized cancer drug testing on patient tumor cells
Aiming to test many FDA-approved cancer drugs on a patient’s own tumor cells to identify effective options when standard therapies fail.
-
MOSAAIC: Using health records to track heart disease in Asian American Communities
A big, dedicated effort is testing whether electronic health records can more quickly and accurately track heart and blood vessel problems in Asian American populations.
-
Targeting gut microbes to prevent progression to multiple myeloma
Researchers are testing how specific gut bacteria might trigger immune changes linked to early blood cancer stages and whether targeting these microbes could help prevent progression to multiple myeloma.
-
eDyNAmiC: Understanding extrachromosomal DNA in cancer and how it drives aggressiveness
A cancer research project at Fred Hutchinson Cancer Center is studying abnormal circular DNA pieces (ecDNA) that help cancers grow and resist treatment, with the aim of finding ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.